everyone worries about brand vs compounded if their pharmacy shuts down. honestly, that’s the wrong question. the real one: does teh new pharmacy actually know what they’re doing? i’d ask: 503A status? reconstitution date on the label? what BAC water they use? how they cold pack and ship? a legit pharmacy answers in under 2 min without getting defensive. they know their protocol cold and stand behind it. sketchy ones hedge or say ‘the vial label covers it.’ that’s ur signal to move on. the brand thing is your prescriber’s call. but the pharmacy’s handling? that’s where ur stability actually lives.
one question that’s worth adding to that list: ask whether they can point you to the actual sterility study that underpins the BUD they print, not just a policy doc saying they follow the 2023 framework. “the vial label covers it” is the hedge you flagged, but plenty of pharmacies with a real release process on the API side still only run a sterility filter pass and a visual inspection on the finished vial, and those are different questions. a solid upstream COA tells you nothing about what shipped. the other thing nobody’s mentioned is that a pharmacy switch is the exact moment to watch your own response data, bc you’re changing source, fill, and sometimes BAC water all at once. if effect drops, you won’t know which variable moved unless you logged a baseline. i keep an open-date field and chart symptom intensity against it in CareClinic.io for that reason, the trend line is what catches a potency shift before i’d blame the new pharmacy outright. transit thaw on a 2-day cold pack is its own clock too, fwiw.
your baseline logging is honestly the only way to catch this - most people switch pharmacies and have no prior data to compare against. but here’s what a COA audit doesn’t show: what happens post-fill. ask the pharmacy specifically how they want you managing the vial between injections and what cold chain they’re expecting at home. that’s where degradation actually happens
“that’s where degradation actually happens” is doing too much work imo. home cold chain is real, but framing it as the whole post-fill story skips two clocks that perfect fridge temps don’t touch: vial open life and BAC water age. you can store a reconstituted vial at a flawless 2-8C and still lose potency to oxidation past the ~30 day mark, because open-vial air exposure isn’t a temperature problem. and the bac water has its own expiry that often runs out before the peptide BUD does. asking the pharmacy how to manage between injections is fine, but the open date is the variable i’d actually be watching.
the under-2-min thing is where i’d push back. confidence isn’t the same as competence and i’ve heard plenty of well-rehearsed answers from pharmacies that turned out to have lousy handling once you actually looked at the COA or the shipper. a tech who’s been there six months can recite a protocol they don’t actually follow, and a pharmacist who pauses to actually check before answering is sometimes the better sign. “answers fast and doesn’t get defensive” is a vibe check, not a quality check. the questions themselves are mostly right but i’d reorder what they tell you. 503A status is a yes/no that every 503A passes, so it doesn’t differentiate. what BAC water they use is also pretty uniform, almost everyone is pulling Hospira or one of the standard 30mL bottles. the two questions that actually separate good from sketchy ime: do they include a LAL/endotoxin result on the COA, and what’s the cold chain look like on the shipper side, specifically how many hours of gel pack at what ambient temp. that’s where the variability lives. purity HPLC numbers are easy to produce. endotoxin testing is the one most research-grade outfits skip and a lot of 503A’s are inconsistent on too. also worth flagging: “503A status” as a quality proxy is doing a lot of work it can’t carry. enforcement varies by state pretty wildly and the gap between two 503A’s in different states can be bigger than the gap between a careful 503A and a reputable research source. not saying that to defend research sources, just that 503A on its own is the floor, not the ceiling. one part that’s solid: “the pharmacy’s handling is where your stability lives.” that’s right and it’s underrated. people pin tank-outs on the molecule when it’s almost always how the vial got from their door to the fridge. ymmv but i’d put the cold chain question above the others.